Investigational drug

Phase 2Small molecule

Pfizer

Investigational drug is one of 111 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Investigational drug

Pfizer

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Completed· Pfizer logo

Pfizer·Phase 2·NCT00034957

Pulmonary Tuberculosis1 trial

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

Active, not recruiting·HHasanuddin University·N/A·NCT07186478·112 enrolled

Metastatic Colorectal Cancer1 trial

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00040391

Multiple Myeloma1 trial

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Completed· Pfizer logo

Pfizer·Phase 1·NCT00036140

Alzheimer's Disease1 trial

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00006187

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Investigational drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigational drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigational drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Investigational drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Cancer1 trial

Pulmonary Tuberculosis1 trial

Metastatic Colorectal Cancer1 trial

Multiple Myeloma1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News